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We support the consensus recommendations from Lineberry
and colleagues for improving the credibility and transparency
of the reporting of adverse events in publications of research
sponsored by industry.1
We also support a similar process for the development of
standards and consensus for the reporting of benefit and harm
outcomes in surgical trials, including early phase surgical
studies. Recent reviews have summarised the heterogeneity of
outcome reporting in many surgical areas,2-6 including in the
evaluation of innovative surgical procedures.7 This limits
evidence syntheses and increases the risk of outcome reporting
bias. For early phase studies, the reporting of selective outcomes
is likely to lead to overoptimistic assessment of new
interventions and under-reporting of adverse effects.
Without systematic and transparent evaluation, as recommended
by Lineberry and colleagues—for example, specifying the
numerators and denominators for all events—surgeons continue
to innovate without reliable information about adverse effects.
This means that the true extent of harm to patients is uncertain
and often only becomes apparent after national registries
summarise outcomes.3 8 This uncertainty could be minimised
by the routine measurement and reporting of adverse events in
early phase surgical studies.
Surgeons must work with industry, the National Office for
Clinical Research Infrastructure, and professional bodies to
urgently develop minimal mandated sets of the benefit and harm
outcomes to measure in each phase of surgical innovation.
Methods developed with the COMET initiative (www.comet-
initiative.org/) enable the identification and categorisation of
benefit and harm outcomes in early phase surgical studies and
the development of minimal mandated sets of benefit and harm
outcomes using consensus methods. Bristol University has
received an NIHR Biomedical Research Centre award to develop
such sets, with the potential to expedite the swift rejection of
unsafe or ineffective techniques and promote the efficient
development of promising innovations.
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